GHK-Cu Cost vs. Alternatives: Comparing Copper Tripeptide to Other Peptides in Its Class

What can actually be compared

HHS's October 2026 draft enforcement-discretion policy for peptides names six substances: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. GHK-Cu is not one of them [6], and it does not appear on FDA's list of bulk drug substances for outsourcing facilities updated March 21, 2025 [7].

Approval status

No FDA-approved drug is known to contain GHK-Cu [1]. Copper histidinate (Zycubo), approved January 12, 2026 for Menkes disease in children, is a different compound [8].

Topical copper peptide creams are sold as cosmetics, which do not need FDA approval before sale; a product intended to treat disease or change body structure or function is legally a drug [2]. Injectable GHK-Cu is not a cosmetic and is not FDA-approved [2]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [9].

Non-injectable GHK-Cu is in category 1 of FDA's interim policy, the group under evaluation for the compounding bulks list; FDA generally does not intend to act against compounders for category 1 substances if its guidance conditions are met [1][5]. It was removed from category 1 on April 22, 2026 when the nominations were withdrawn, and added back (list updated May 14, 2026) after a nominator clarified on May 5 that only the injectable route had been withdrawn [1][5]. FDA has announced it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027; no vote has happened [1].

Injectable GHK-Cu is in FDA's nominated-but-withdrawn table. FDA's stated concern: compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and there are limited data in humans to inform safety-related considerations [3].

Human evidence

Two randomized human trials were found, both small. In one, 13 patients had circumoral skin resurfaced with a CO2 laser and used post-treatment care with or without GHK-Cu; computer analysis and blinded evaluators found no significant difference in redness resolution, wrinkles or overall skin quality, while a patient questionnaire favored GHK-Cu (P=.04) [10]. In the other, 86 evaluable patients with venous stasis ulcers received a 0.4% tripeptide copper complex cream, an inert vehicle placebo, or silver sulfadiazine 1%; the copper cream was no different from placebo for ulcer size, while silver sulfadiazine reduced ulcer size [11]. A 2026 systematic review kept 64 records from a 2005 to 2026 search and described the human literature as thin and fragmented, with most randomized trials small and run on facial cosmetic creams [12].

A review by the researchers who proposed the mechanism states that GHK can up- and downregulate at least 4,000 human genes. That is gene-expression and laboratory work, not a clinical outcome in patients [4].

How claims decide whether a topical product is a drug

FDA gives claims to restore hair growth, reduce cellulite or regenerate cells as examples of drug claims, and the FD&C Act does not recognize a category called cosmeceuticals [2]. HealthRX.com offers a copper peptide cream.